Terpene-enhanced olaminogel for superior vaginal permeation: robust assessment through in vitro, microbiological, ex vivo, and in vivo evaluations

Vulvovaginal fungal infections remain a major therapeutic challenge due to poor drug penetration, recurrence, and limited efficacy of conventional formulations. Harnessing nanotechnology with a novel delivery platform offers a promising strategy to overcome these barriers. In this study, an innovative olaminogel was designed as an advanced nanocarrier for terconazole (TCZ) to enhance local antifungal therapy via the vaginal route. The formulation was prepared using the ethanol injection method and systematically optimized through a 2<sup>3</sup> factorial design considering limonene-to-surfactant ratio (factor A), oleylamine-to-drug ratio (factor B), and oleic acid-to-surfactant ratio (factor C). Optimization targeted maximal entrapment efficiency (EE%), minimal particle size (PS), and stable zeta potential (ZP). The optimized olaminogel achieved an EE% of 82.11, nano-metric PS of 217.25 nm, and a ZP of - 33.05 mV. TEM confirmed well-formed vesicles, while FTIR verified successful encapsulation. Further in vitro characterization revealed pseudo-plastic rheology, sustained biphasic drug release, and stability for 3 months. Mucoadhesion testing demonstrated strong adhesion of the olaminogel to vaginal mucosa. Ex vivo permeation across rabbit vaginal mucosa demonstrated significantly deeper penetration (180 µm vs. 55 µm) compared with plain TCZ gel, corroborated by in vivo CLSM imaging. Histopathological studies further confirmed biocompatibility and absence of irritation. Importantly, microbiological evaluation revealed markedly reduced MIC and MFC values, alongside an accelerated fungicidal effect, outperforming TCZ control. Collectively, these findings highlight olaminogel as a novel and potent intravaginal nanocarrier capable of improving drug retention, mucosal penetration, and antifungal efficacy, thereby presenting a next-generation platform for safe and effective management of vaginal fungal infections.

Authors

Institutions

Publication Details

Journal
Naunyn-Schmiedeberg s Archives of Pharmacology
Published
2025-12-19
DOI
https://doi.org/10.1007/s00210-025-04838-w
Citations
7
Primary Topic
Advancements in Transdermal Drug Delivery
Type
article
Field-Weighted Citation Impact
5.54

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Terpene-enhanced olaminogel for superior vaginal permeation: robust assessment through in vitro, microbiological, ex vivo, and in vivo evaluations

Manal M. El-Ashmoony, Heba Attia, Sadek Ahmed, Dina Mehana
7 citations
Naunyn-Schmiedeberg s Archives of Pharmacology
Advancements in Transdermal Drug Delivery
5.54
article

Terpene-enhanced olaminogel for superior vaginal permeation: robust assessment through in vitro, microbiological, ex vivo, and in vivo evaluations

Manal M. El-Ashmoony, Heba Attia, Sadek Ahmed, Dina Mehana
article en
7 citations

Abstract

Vulvovaginal fungal infections remain a major therapeutic challenge due to poor drug penetration, recurrence, and limited efficacy of conventional formulations. Harnessing nanotechnology with a novel delivery platform offers a promising strategy to overcome these barriers. In this study, an innovative olaminogel was designed as an advanced nanocarrier for terconazole (TCZ) to enhance local antifungal therapy via the vaginal route. The formulation was prepared using the ethanol injection method and systematically optimized through a 2<sup>3</sup> factorial design considering limonene-to-surfactant ratio (factor A), oleylamine-to-drug ratio (factor B), and oleic acid-to-surfactant ratio (factor C). Optimization targeted maximal entrapment efficiency (EE%), minimal particle size (PS), and stable zeta potential (ZP). The optimized olaminogel achieved an EE% of 82.11, nano-metric PS of 217.25 nm, and a ZP of - 33.05 mV. TEM confirmed well-formed vesicles, while FTIR verified successful encapsulation. Further in vitro characterization revealed pseudo-plastic rheology, sustained biphasic drug release, and stability for 3 months. Mucoadhesion testing demonstrated strong adhesion of the olaminogel to vaginal mucosa. Ex vivo permeation across rabbit vaginal mucosa demonstrated significantly deeper penetration (180 µm vs. 55 µm) compared with plain TCZ gel, corroborated by in vivo CLSM imaging. Histopathological studies further confirmed biocompatibility and absence of irritation. Importantly, microbiological evaluation revealed markedly reduced MIC and MFC values, alongside an accelerated fungicidal effect, outperforming TCZ control. Collectively, these findings highlight olaminogel as a novel and potent intravaginal nanocarrier capable of improving drug retention, mucosal penetration, and antifungal efficacy, thereby presenting a next-generation platform for safe and effective management of vaginal fungal infections.

Naunyn-Schmiedeberg s Archives of Pharmacology
Cairo University (EG), University of Sadat City (EG), Ain Shams University Hospital (EG)
Science and Technology Development Fund
Openalex Percentile: Top 4%
Advancements in Transdermal Drug Delivery
5.54
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.